{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:08:50Z","timestamp":1780805330447,"version":"3.54.1"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.2169\/internalmedicine.9479-17","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T17:15:36Z","timestamp":1514308536000},"page":"1219-1227","source":"Crossref","is-referenced-by-count":5,"title":["Differences in the Serum 4\u03b2-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment"],"prefix":"10.2169","volume":"57","author":[{"given":"Takeshi","family":"Hirayama","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Japan"},{"name":"Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho-Ichiro","family":"Yara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Kohjima","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58: 655-662, 2013.","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"2. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58: 646-654, 2013.","DOI":"10.1016\/j.jhep.2012.11.012"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Asahina Y, Izumi N, Hiromitsu K, et al. JSH Guidlines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. Hepatol Res 46: 129-165, 2016.","DOI":"10.1111\/hepr.12645"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bodin K, Bretillon L, Aden Y, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276: 38685-38689, 2001.","DOI":"10.1074\/jbc.M105127200"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bodin K, Andersson U, Rystedt E, et al. Metabolism of 4 beta-hydroxycholesterol in humans. J Biol Chem 277: 31534-31540, 2002.","DOI":"10.1074\/jbc.M201712200"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kanebratt KP, Diczfalusy U, Backstrom T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 84: 589-594, 2008.","DOI":"10.1038\/clpt.2008.132"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kasichayanula S, Boulton DW, Luo WL, et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br J Clin Pharmacol 78: 1122-1134, 2014.","DOI":"10.1111\/bcp.12425"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Leil TA, Kasichayanula S, Boulton DW, LaCreta F. Evaluation of 4beta-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model. CPT Pharmacometrics Syst Pharmacol 3: e120, 2014.","DOI":"10.1038\/psp.2014.18"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Honda A, Miyazaki T, Ikegami T, et al. Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS\/MS. J Steroid Biochem Mol Biol 121: 556-564, 2010.","DOI":"10.1016\/j.jsbmb.2010.03.030"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Honda A, Yamashita K, Hara T, et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS\/MS. J Lipid Res 50: 350-357, 2009.","DOI":"10.1194\/jlr.D800040-JLR200"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Honda A, Yamashita K, Miyazaki H, et al. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS\/MS. J Lipid Res 49: 2063-2073, 2008.","DOI":"10.1194\/jlr.D800017-JLR200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One 10: e0130022, 2015.","DOI":"10.1371\/journal.pone.0130022"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Miyazaki T, Honda A, Ikegami T, et al. Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. Hepatol Res 41: 530-541, 2011.","DOI":"10.1111\/j.1872-034X.2011.00803.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ikegami T, Honda A, Miyazaki T, Kohjima M, Nakamuta M, Matsuzaki Y. Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem Biophys Res Commun 446: 736-740, 2014.","DOI":"10.1016\/j.bbrc.2014.01.176"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18: 201-208, 2008.","DOI":"10.1097\/FPC.0b013e3282f50ee9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44: 275-283, 1992.","DOI":"10.1016\/0006-2952(92)90010-G"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Aubry AF, Dean B, Diczfalusy U, et al. Recommendations on the development of a bioanalytical assay for 4beta-hydroxycholesterol, an emerging endogenous biomarker of CYP3A activity. AAPS J 18: 1056-1066, 2016.","DOI":"10.1208\/s12248-016-9949-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Werk AN, Lefeldt S, Bruckmueller H, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther 95: 416-422, 2014.","DOI":"10.1038\/clpt.2013.210"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol 52: 94-103, 2016.","DOI":"10.1007\/s00535-016-1225-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52: 854-863, 2010.","DOI":"10.1002\/hep.23796"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ogawa E, Furusyo N, Kajiwara E, et al. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Res 104: 102-109, 2014.","DOI":"10.1016\/j.antiviral.2014.01.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One 11: e0163644, 2016.","DOI":"10.1371\/journal.pone.0163644"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 57: 1931-1941, 2013.","DOI":"10.1002\/hep.26018"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385: 1075-1086, 2015.","DOI":"10.1016\/S0140-6736(14)61795-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/9\/57_9479-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T23:32:14Z","timestamp":1525476734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/9\/57_9479-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9479-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}